https://www.yiliao.com/index.php?action=history&feed=atom&title=P40_%28%E5%85%8D%E7%96%AB%E5%AD%A6%29
P40 (免疫学) - 版本历史
2026-04-18T18:59:13Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=P40_(%E5%85%8D%E7%96%AB%E5%AD%A6)&diff=315707&oldid=prev
2026年1月26日 (一) 02:19 77921020
2026-01-26T02:19:39Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月26日 (一) 02:19的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >第1行：</td>
<td colspan="2" class="diff-lineno">第1行：</td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">记录排行榜</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">请输入搜索内容</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">帖子</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">搜索</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">热搜:活动交友discuz</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">基因医生»论坛›first›医学百科›医学百科›P40</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">返回列表发新帖回复</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">删除主题|升降|置顶|直播|高亮|精华|图章|图标|关闭|移动|分类|复制|合并|分割|修复|警告|屏蔽|标签|生成文章</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">查看: 0|回复: 0</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"> P40 [复制链接]</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">admin</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">449</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">主题 </del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">337</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">回帖 </del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">2475</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">积分</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">管理员</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">积分2475</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">IP编辑禁止帖子清理</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">电梯直达</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">楼主</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"> 楼主| 发表于 1 秒前 | 只看该作者 </del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=P40_(%E5%85%8D%E7%96%AB%E5%AD%A6)&diff=315706&oldid=prev
77921020：建立内容为“记录排行榜 请输入搜索内容 帖子 搜索 热搜:活动交友discuz 基因医生»论坛›first›医学百科›医学百科›P40 返回列表发新…”的新页面
2026-01-26T02:19:06Z
<p>建立内容为“记录排行榜 请输入搜索内容 帖子 搜索 热搜:活动交友discuz 基因医生»论坛›first›医学百科›医学百科›P40 返回列表发新…”的新页面</p>
<p><b>新页面</b></p><div>记录排行榜<br />
请输入搜索内容<br />
帖子<br />
搜索<br />
热搜:活动交友discuz<br />
基因医生»论坛›first›医学百科›医学百科›P40<br />
返回列表发新帖回复<br />
删除主题|升降|置顶|直播|高亮|精华|图章|图标|关闭|移动|分类|复制|合并|分割|修复|警告|屏蔽|标签|生成文章<br />
查看: 0|回复: 0<br />
P40 [复制链接]<br />
admin<br />
<br />
449<br />
<br />
主题 <br />
337<br />
<br />
回帖 <br />
2475<br />
<br />
积分<br />
管理员<br />
<br />
<br />
积分2475<br />
IP编辑禁止帖子清理<br />
<br />
电梯直达<br />
楼主<br />
楼主| 发表于 1 秒前 | 只看该作者 <br />
<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>p40</strong>（基因符号：<strong>[[IL12B]]</strong>）是免疫学中著名的“共享亚基”，它是细胞因子 <strong>[[IL-12]]</strong> 和 <strong>[[IL-23]]</strong> 共有的结构组分。作为一个 40 kDa 的糖蛋白，p40 就像一个通用的“分子适配器”：当它与 p35 亚基结合时形成 IL-12，驱动 <strong>[[Th1细胞]]</strong> 免疫；当它与 p19 亚基结合时则形成 IL-23，维持 <strong>[[Th17细胞]]</strong> 轴。这种独特的双重角色使得 p40 成为治疗银屑病、克罗恩病等自身免疫性疾病的重磅靶点。针对 p40 的单克隆抗体（如<strong>[[乌司奴单抗]]</strong>）能够通过“一石二鸟”的机制，同时切断 Th1 和 Th17 两条主要的炎症通路。此外，p40 还可以形成同源二聚体（p80），在某些情境下作为天然拮抗剂发挥调节作用。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">p40 Subunit</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">IL-12/IL-23 Shared Chain · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[Image:IL-12B_p40_structure_diagram.png|100px|p40 亚基结构示意图]]</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">共享链 / 炎症枢纽</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">基因符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>IL12B</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">染色体位置</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">5q31.1 (细胞因子簇)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">蛋白类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">I型细胞因子亚基</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">40 kDa (糖基化)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">结合受体</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[IL-12Rβ1]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">配对亚基</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">p35 (IL-12), p19 (IL-23)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">靶向药物</th><br />
<td style="padding: 12px; color: #0f172a;">[[乌司奴单抗]] (Ustekinumab)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：双重身份与信号锚点</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
p40 亚基不仅是结构的支撑者，更是信号特异性的第一道关卡。它的存在定义了免疫反应的类型：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>结构基础：</strong> p40 具有类似免疫球蛋白（Ig-like）的 β-三明治结构，类似于细胞因子受体的胞外域。这种结构使其能够稳定地与具有螺旋束结构的 p35 或 p19 结合，形成有生物活性的异源二聚体。</li><br />
<li style="margin-bottom: 12px;"><strong>受体锚定：</strong> p40 负责结合靶细胞表面的高亲和力受体链 <strong>[[IL-12Rβ1]]</strong>。<br />
<br><em>信号分流：</em> 一旦 p40 锚定受体，另一侧的亚基（p35 或 p19）则分别招募 IL-12Rβ2 或 IL-23R，从而决定是激活 [[STAT4]] (Th1) 还是 [[STAT3]] (Th17)。</li><br />
<li style="margin-bottom: 12px;"><strong>过量分泌与调节：</strong> 在炎症状态下，p40 的产量通常远高于 p35。过剩的 p40 可形成同源二聚体 (p40)2，即 <strong>p80</strong>。研究表明 p80 可竞争性结合 IL-12Rβ1，充当天然的 IL-12 拮抗剂。</li><br />
</ul><br />
[[Image:p40_subunit_IL12_IL23_shared_mechanism.png|100px|p40 共享机制示意图]]<br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价矩阵：靶向 p40 的双阻断策略</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床场景</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">分子逻辑</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">疗效与地位</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[银屑病]] (Psoriasis)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">同时抑制 IL-12/Th1 和 IL-23/Th17</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">抗 p40 单抗（乌司奴单抗）是该领域的里程碑药物，证实了阻断 IL-12/23 轴比阻断 TNF-α 具有更好的皮损清除率。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[克罗恩病]] (CD)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">肠道炎症由 Th1/Th17 混合驱动</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">p40 阻断剂是中重度 CD 的一线生物制剂，尤其适用于对 TNF 抑制剂失应答的患者。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">MSMD (遗传缺陷)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">IL12B 基因功能丧失性突变</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">p40 缺失导致患者无法产生 IFN-γ，从而对弱毒力分枝杆菌（如 BCG 疫苗）表现出极高的易感性。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗前沿：特异性 vs 泛阻断</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
随着针对 IL-23 特异性亚基（p19）药物的问世，p40 靶向疗法面临新的审视：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>安全性辩论：</strong> 长期阻断 p40 意味着同时也抑制了 IL-12 介导的抗肿瘤和抗胞内感染免疫。虽然临床数据显示乌司奴单抗安全性极佳，但在有恶性肿瘤风险的患者中，仅阻断 p19（保留 IL-12/p35 功能）可能在理论上更为安全。</li><br />
<li style="margin-bottom: 12px;"><strong>新一代开发：</strong> 目前并未停止对 p40 的研究，新型口服小分子药物正在尝试阻断 p40 与受体的相互作用界面，以期实现非抗体类的免疫调节。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Wolf SF, et al. (1991).</strong> <em>Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic activities.</em> <strong>[[Journal of Immunology]]</strong>.<br><br />
<span style="color: #475569;">[发现之源]：首次克隆了 p40 基因，揭示了其与 p35 形成异源二聚体（IL-12）的结构基础，同时也注意到了 p40 基因与造血细胞因子受体的同源性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Oppmann B, et al. (2000).</strong> <em>Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.</em> <strong>[[Immunity]]</strong>.<br><br />
<span style="color: #475569;">[关键转折]：发现了 p40 的“第二伙伴” p19，从而定义了 IL-23。这一发现解释了为何 p40 敲除小鼠的表型比 p35 敲除小鼠更为严重，因为 p40 缺失同时消除了 Th1 和 Th17 反应。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Leonardi CL, et al. (2008).</strong> <em>Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis.</em> <strong>[[The Lancet]]</strong>.<br><br />
<span style="color: #475569;">[临床实证]：PHOENIX 1 试验确立了靶向 p40 在自身免疫病治疗中的临床价值，开启了抗 IL-12/23 治疗的新时代。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
p40 (IL12B) 亚基交互生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">复合产物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[IL-12]] (p35+p40)•[[IL-23]] (p19+p40)•[[p80同源二聚体]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">拮抗药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[乌司奴单抗]] (Ustekinumab)•[[Briakinumab]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联受体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[IL-12Rβ1]] (必选)•[[IL-12Rβ2]] (IL-12特异)•[[IL-23R]] (IL-23特异)</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">相关疾病</td><br />
<td style="padding: 10px 15px; color: #334155;">[[银屑病]]•[[克罗恩病]]•[[MSMD]] (孟德尔遗传易感性)•[[溃疡性结肠炎]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020